{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"anti-B7-H3/DXd ADC DS-7300a"},{"type":"Synonym","name":"anti-B7H3/DXd antibody-drug conjugate DS-7300a"},{"type":"CodeName","name":"DS 7300"},{"type":"CodeName","name":"DS 7300a"},{"type":"CodeName","name":"DS7300"},{"type":"CodeName","name":"DS7300a"},{"type":"CASRegistryName","name":"2484870-92-8"},{"type":"Synonym","name":"anti-B7-H3/DXd antibody-drug conjugate DS-7300a"},{"type":"CodeName","name":"DS-7300"},{"type":"CodeName","name":"DS-7300a"}],"definition":{"html":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via an enzymatically cleavable tetrapeptide-based linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951) derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the anti-B7-H3/DXd ADC DS-7300a, the anti-B7-H3 antibody targets and binds to B7-H3-expressing tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It plays a key role in tumor growth and immune responses. The ADC allows for reduced systemic exposure and enhanced delivery of the cytotoxic agent DXd.","text":"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via an enzymatically cleavable tetrapeptide-based linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951) derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the anti-B7-H3/DXd ADC DS-7300a, the anti-B7-H3 antibody targets and binds to B7-H3-expressing tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It plays a key role in tumor growth and immune responses. The ADC allows for reduced systemic exposure and enhanced delivery of the cytotoxic agent DXd."},"drugInfoSummaryLink":null,"nciConceptId":"C171577","nciConceptName":"Ifinatamab Deruxtecan","termId":801901,"name":"ifinatamab deruxtecan","firstLetter":"i","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"ifinatamab-deruxtecan"}],"links":null}